Study of OSI-774 (Tarceva) in Previously Untreated Elderly Lung Cancer Patients

Completed · Phase 2

Conditions studied: Non-Small-Cell Lung Carcinoma

In brief

The primary purpose of this study is to determine whether the drug OSI-774 is less toxic and potentially as good as or better than standard chemotherapy drugs, when given to subjects with non-small cell lung cancer, who are 70 years of age or older.

Key facts

Study ID
NCT00137800
Run by
Dana-Farber Cancer Institute
People needed
82
Starts
2003-02-01
Expected to finish
2007-03-01
Last updated by the study team
2020-04-03

Who can join

Age: 70 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.